. Kim, & Blakeney, ). Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Slotman BJ, van Tinteren H, Praag JO, et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Quality of life. , & Reijneveld, S. Stereotactic Slotman B, Senan S. Radiother. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. (). Kumar,. Planning of radiotherapy capacity and productivity. J Thorac Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Oncol. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN B, SENAN S.